(NASDAQ: LPTX) Leap Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.32%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.27%.
Leap Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast LPTX's revenue for 2025 to be $2,649,614,180, with the lowest LPTX revenue forecast at $2,649,614,180, and the highest LPTX revenue forecast at $2,649,614,180. On average, 2 Wall Street analysts forecast LPTX's revenue for 2026 to be $2,686,862,379, with the lowest LPTX revenue forecast at $153,600,822, and the highest LPTX revenue forecast at $5,220,123,936.
In 2027, LPTX is forecast to generate $4,157,462,249 in revenue, with the lowest revenue forecast at $739,075,955 and the highest revenue forecast at $7,575,848,542.